Trial Profile
An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 May 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Dravet syndrome; Lennox-Gastaut syndrome
- Focus Adverse reactions; Registrational
- Acronyms GWPCARE 5
- Sponsors GW Research; Jazz Pharmaceuticals Inc
- 26 Apr 2022 Results of post hoc pooled analysis evaluating effect of dose adjustments on efficacy and safety of CBD in patients from NCT02224560 and NCT02224573 ,presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 18 Aug 2021 Interim results (data cut off: December 3, 2019) assessing the safety, efficacy and patient-reported outcomes from GWPCARE5 published in the Epilepsia
- 20 Jul 2021 Results(n=366)for Safety analyses results of a long-term open-label extension trial published in the Epilepsia